These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 26582803)
1. Development of an HTRF Assay for the Detection and Characterization of Inhibitors of Catechol-O-Methyltransferase. Kimos M; Burton M; Urbain D; Caudron D; Martini M; Famelart M; Gillard M; Barrow J; Wood M J Biomol Screen; 2016 Jun; 21(5):490-5. PubMed ID: 26582803 [TBL] [Abstract][Full Text] [Related]
2. [Inhibition of catechol-O-methyltransferase. Optimizing dopaminergic therapy in idiopathic Parkinson syndrome with entacapone]. Arnold G; Kupsch A Nervenarzt; 2000 Feb; 71(2):78-83. PubMed ID: 10703007 [TBL] [Abstract][Full Text] [Related]
3. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients. Müller T; Kuhn W Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261 [TBL] [Abstract][Full Text] [Related]
10. Medicinal chemistry of catechol O-methyltransferase (COMT) inhibitors and their therapeutic utility. Kiss LE; Soares-da-Silva P J Med Chem; 2014 Nov; 57(21):8692-717. PubMed ID: 25080080 [TBL] [Abstract][Full Text] [Related]
11. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase. Vieira-Coelho MA; Soares-da-Silva P Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789 [TBL] [Abstract][Full Text] [Related]
12. New pharmacotherapy for Parkinson's disease. Gottwald MD; Bainbridge JL; Dowling GA; Aminoff MJ; Alldredge BK Ann Pharmacother; 1997 Oct; 31(10):1205-17. PubMed ID: 9337447 [TBL] [Abstract][Full Text] [Related]
13. Inhibitors of catechol-O-methyltransferase in the treatment of neurological disorders. Jatana N; Apoorva N; Malik S; Sharma A; Latha N Cent Nerv Syst Agents Med Chem; 2013; 13(3):166-94. PubMed ID: 24450388 [TBL] [Abstract][Full Text] [Related]
14. The place of COMT inhibitors in the armamentarium of drugs for the treatment of Parkinson's disease. Schapira AH; Obeso JA; Olanow CW Neurology; 2000; 55(11 Suppl 4):S65-8; discussion S69-71. PubMed ID: 11147512 [TBL] [Abstract][Full Text] [Related]
15. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Kaakkola S Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464 [TBL] [Abstract][Full Text] [Related]
16. New options for treatment of Parkinson's disease. LeWitt PA Baillieres Clin Neurol; 1997 Apr; 6(1):109-23. PubMed ID: 9426871 [TBL] [Abstract][Full Text] [Related]
17. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro. Gerlach M; Ukai W; Ozawa H; Riederer P J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468 [TBL] [Abstract][Full Text] [Related]
18. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. Borges N; Vieira-Coelho MA; Parada A; Soares-da-Silva P J Pharmacol Exp Ther; 1997 Aug; 282(2):812-7. PubMed ID: 9262345 [TBL] [Abstract][Full Text] [Related]